~~<i id='67CE608C41'><strike id='67CE608C41'><tt id='67CE608C41'><pre id='67CE608C41'></pre></tt></strike></i>~~

Home» Wikipedia» Wikipedia

Wikipedia

author：comprehensive 2025-09-29 07:26:34 Page View：3

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Researchers explore possible ties between long Covid, menopause
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

FDA warns J&J's Abiomed: We will regulate your software

Abiomed,whichwasboughtbyJohnson&Johnsonlatelastyearfor$16.6billion,sellsdevicesforheartfailurepa

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Hospital price transparency does save money, advocate argues

CynthiaFisher,founderandchairman,PatientRightsAdvocate.orgSTATBOSTON—Forallthosewhothinkhospitalpric